ARTICLE

Turn-on chemiluminescence probes and dual-amplification of signal for detection of amyloid beta species in vivo

Jing Yang1,5, Wei Yin1,5, Richard Van2, Keyi Yin1, Peng Wang1, Chao Zheng1, Biyue Zhu1, Kathleen Ran1, Can Zhang3, Mohanraja Kumar4, Yihan Shao2 & Chongzhao Ran1

Turn-on fluorescence imaging is routinely studied; however, turn-on chemiluminescence has been rarely explored for in vivo imaging. Herein, we report the design and validation of chemiluminescence probe ADLumin-1 as a turn-on probe for amyloid beta (Aβ) species. Two-photon imaging indicates that ADLumin-1 can efficiently cross the blood–brain barrier and provides excellent contrast for Aβ plaques and cerebral amyloid angiopathy. In vivo brain imaging shows that the chemiluminescence signal of ADLumin-1 from 5-month-old transgenic 5xFAD mice is 1.80-fold higher than that from the age-matched wild-type mice. Moreover, we demonstrate that it is feasible to further dually-amplify signal via chemiluminescence resonance energy transfer (DAS-CRET) using two non-conjugated smart probes (ADLumin-1 and CRANAD-3) in solutions, brain homogenates, and in vivo whole brain imaging. Our results show that DAS-CRET can provide a 2.25-fold margin between 5-month-old 5xFAD mice and wild type mice. We believe that our strategy could be extended to other aggregating-prone proteins.

https://doi.org/10.1038/s41467-020-17783-4

1Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital/Harvard Medical School, Room 2301, Building 149, Charlestown, Boston, MA 02129, USA. 2Department of Chemistry and Biochemistry, University of Oklahoma, Norman, OK 73019, USA. 3Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA. 4Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA, USA. 5These authors contributed equally: Jing Yang, Wei Yin. ✉email: cran@nmr.mgh.harvard.edu
Optical imaging has been widely applied in preclinical and clinical studies. Among the optical imaging modalities, near infrared fluorescence imaging (NIRF) is one of the most used technologies for preclinical investigations. However, NIRF imaging has several intrinsic limitations that are caused by excitation light, which is needed as input light to excite the imaging probe. First, for a biological sample, the excitation light not only excites the fluorescent probe, but also other fluorophore-containing molecules in the sample to cause troublesome autofluorescence. Second, due to the Stokes shift, the wavelength of excitation is always much shorter than the emission wavelength, while the tissue penetration is reversely correlated with the wavelength, therefore the excitation at a relatively shorter wavelength could be problematic in penetrating the biological sample. Third, a fluorescent probe with small Stokes shift suffers from the interference from excitation leakage in real imaging practice due to the imperfection of filters in imaging systems. Fourth, the excitation light generates relatively much stronger emission signals from fluorophores at shallow locations, which contain nonspecifically accumulated imaging probe and auto-fluorescent molecules. Therefore, excitation-related limitations of NIRF imaging are significantly contributed to low signal to noise ratio (SNR) and poor tissue penetration. Fortunately, the problems of fluorescence imaging can be partially resolved by chemi or bioluminescence imaging, which do not require external excitation light. Therefore, compared to NIRF imaging, chemi or bioluminescence imaging can provide much better tissue penetration at the same emission wavelength. A recent study demonstrated that 4-cm tissue penetration could be achieved with chemiluminescence imaging at an 800 nm emission, while NIRF demonstrated that 4-cm tissue penetration could be achieved with bioluminescence imaging can provide much better tissue penetration.

However, compared to fluorescence imaging, chemiluminescence imaging is being applied far less in biological studies, primarily due to its low sensitivity and irreversibility of the probes. Another drawback of chemiluminescence is the need of a chemical reaction to produce the emission light. Another drawback of chemiluminescence is the need of a chemical reaction to produce the emission light. Moreover, some of the scaffolds have intrinsic limitations for brain imaging. For example, lucigenin and acridinium have charges and are very polar, which can lead to poor brain penetration. Oxlolate ester is difficult to extend the wavelength, while dioxetane are not always very stable. In this report, we selected imidazo[1,2-a]pyrazin-3(7H)-one (IPO) as the scaffold (Moiety A in Fig. 1a), due to its easy modifiability for wavelength extension and high stability.

Our probe design is expected to meet the following requirements. First, the designed compounds should bind strongly to Aβs. In this regard, we surveyed the structures of fluorescence dyes that are sensitive to Aβs, and found numerous dyes containing moiety B (Fig. 1a), which has the potential to insert into the beta sheet of Aβs. Second, the probe should have turn-on capacity upon Aβ binding. Since moiety B is a hydrophobic and planar fragment, it could interact with the hydrophobic segment of Aβs. Consequently, the interaction could lead to turn-on chemiluminescence. Third, the designed probes should have longer emissions. To achieve this, the connection between moiety A and B should allow electrons to delocalize, which can lead to a smaller energy gap between HOMO and LUMO. Based on the above considerations, we designed ADLumin-1 and -2 (Fig. 1a, b), in which moiety A is responsible for generating chemiluminescence and moiety B is for binding to Aβs, and moieties A and B are connected via double bonds that can make the electrons delocalize across the whole molecule. The synthesis of ADLumin-X (X = 1, 2) is very straightforward and the route is shown in Fig. 1c.

Spectral characterization and validation of the turn-on feature. Normally, all chemiluminescent molecules are fluorescent. We recorded the excitation and emission spectra of ADLumin-X, and found that the emission peak of ADLumin-1 was around 590 nm (Supplementary Fig. 1) in DMSO, which is considerably longer than most of the commercially available chemiluminescence probes. We had expected the emission of ADLumin-2 to be longer than that of ADLumin-1, due to its additional double-bond. Indeed, the emission peak of ADLumin-2 was 20 nm longer. However, we found that the quantum yield (QY) of ADLumin-2 was significantly decreased (Φ_{ADLumin-2}/Φ_{ADLumin-1} = 0.67). Based on this fact, we decided to utilize ADLumin-1 for our further investigation, due to its high QY.

ADLumin-1 is stable in PBS buffer and organic solvents, including acetoniitrile, dichloromethane, and methanol. However, interestingly, we found that in the presence of 10% DMSO, ADLumin-1 is luminescent, and the emission peak was around 540 nm (Fig. 2a). We speculated that the luminescence was due to...
the auto-oxidation of ADLumin-1. Although the mechanism of chemiluminescence of IOP derivatives has been studied, the mechanism of auto-oxidation has been rarely explored\(^5\). In the course of our experiments, we noticed that ADLumin-1 emitted very strong luminescence in pure DMSO (Fig. 2b). However, ADLumin-1 showed no apparent chemiluminescence in other solvents, including methanol, ethyl acetate, dichloromethane. Unexpectedly, if the ADLumin-1 DMSO solution was stirred, even stronger luminescence can be detected (3.4-fold in Fig. 2b). We speculated that the luminescence was related to oxygen levels in DMSO. To validate our hypothesis, we intermittently bubbled O\(_2\) in the DMSO solution 5 s for several rounds, and found that the intensities were dramatically increased (27-fold) after first bubbling. However, the increasing-fold decreased with cycles (Fig. 2c). LC-MS indicated that ADLumin-1 was converted into a new compound, termed as ADLumin-3 (Fig. 2d), whose structure was further con\(^f\)irmed by \(^1\)H-NMR, \(^{13}\)C-NMR, and HR-MS.

Since no ROS were added into the DMSO solution, we cautiously concluded that the auto-oxidation of ADLumin-1 was oxygen-level dependent. It is worthy to note that green fluorescent protein and luciferase/luciferin are also dependent on oxygen for their proper imaging functions\(^5\).\(^3\),\(^4\).

We also investigated the responses of ADLumin-1 towards different ROS species, and found that the intensity increasing was considerably lower, compared to the increasing in the presence of O\(_2\) bubbling (Supplementary Fig. 2A, B), again suggesting that the auto-oxidation is the primary cause of chemiluminescence of ADLumin-1. We have proposed a tentative mechanism for the auto-oxidation in Fig. 2c, in which O\(_2\) is added to the double-bond of imidazole moiety to form an unstable intermediate that further decomposes into ADLumin-3 and releases photons (light). Full elucidation of the mechanism needs more intensive investigation.

To investigate whether ADLumin-1 can bind to A\(\beta\)s, we first recorded the fluorescence spectra before and after the addition of A\(\beta\)40 aggregates. As expected, ADLumin-1 was a smart fluorescence probe, evident by a 100-fold fluorescence intensity increasing upon mixing with A\(\beta\)s (Fig. 3a). Moreover, we found that there was a significant blue-shift of emission of the probe with A\(\beta\)s (Supplementary Fig. 2A), suggesting the probe binds to the hydrophobic fragment of A\(\beta\)s. We also measured the K\(d\) via concentration titration, and K\(d\) = 2.1 uM (Supplementary Fig. 2B).

To investigate whether there is a significant chemiluminescence intensity increase upon incubation with A\(\beta\)s, we tested ADLumin-1 in PBS buffer (with 5% DMSO). Similar to the fluorescence response, the chemiluminescence was dramatically turned-on, and the increase was about 216-fold at 540 nm (Fig. 3b). We also conducted molecule docking studies for ADLumin-1 with A\(\beta\) fibrils. The docking was based on the cryo-EM structure of A\(\beta\)42 (PDB:5OQV), and the results suggested that ADLumin-1 preferred to bind to the hydrophobic groove formed by Phe19, Ala21, Val24, Asn27, and Ile31 (Fig. 3c). This hydrophobic binding is consistent with the blue-shift of the fluorescence spectrum of ADLumin-1 in the presence of A\(\beta\) aggregates (Supplementary Fig. 2A, C). We have also incubated...
ADLumin-1 with Aβ oligomers in PBS solution and found no significant change of chemiluminescence intensity. These results suggested that ADLumin-1 had specific binding with Aβ fibrils.

To investigate whether an IVIS imaging system could be used to detect the increase of chemiluminescence of ADLumin-1 with Aβ fibrils, we performed experiments with open filter setting on a 96-well plate. Indeed, the signal was 104-fold higher from the wells with Aβ fibrils than that from wells without Aβ fibrils (Fig. 3d, e). Though numerous fluorescence probes and smart (turn-on) probes have been reported for Aβ fibrils in the past decades, it is worth noting that ADLumin-1, to the best of our knowledge, is the first smart chemiluminescence probe for Aβ fibrils.

To explore whether the smart chemiluminescence probe can be used in a real biological environment, we incubated ADLumin-1 with mouse brain homogenate in the presence and absence of Aβ aggregates (12.5 μM). Remarkably we found that ADLumin-1 provided much higher signal from the Aβ group, and the difference was about 11.6-fold (Fig. 3f, g). The intensity increasing was linear to Aβ concentrations in the range of 0–12.5 μM (Supplementary Fig. 3C). Interestingly, MCLA, a commercially available chemiluminescence compound containing IPO moiety, showed significantly reduced signal with Aβ fibrils (Supplementary Fig. 4A, B). The underlying mechanism of the different chemiluminescence responses of MCLA and ADLumin-1 towards Aβ species is still under our investigation.

During the spectral studies, we noticed that the full width at half-maximum (FWHM) of ADLumin-1 was considerably large (94 nm, Fig. 4a). We hypothesized that, for a probe with a relatively short emission peak (540 nm), the larger FWHM could be beneficial for in vivo studies. To validate this hypothesis, we compared ADLumin-1 to widely used firefly luciferin (peak at 570 nm, FWHM = 83 nm), which has been proven to have excellent tissue penetration. In our experiment, we placed a tube that had similar intensity of emitted light from ADLumin-1 or firefly luciferin (with luciferase) (Fig. 4b) under the abdomen of a nude mouse (the depth is about 1.5 cm) (Fig. 4c), and then collected the signals with an IVIS imaging system, which captured the signals from the dorsal side. We found that ADLumin-1 provided comparable signals to firefly luciferin (Fig. 4c, d). There was about 5% of the light that penetrated through the whole body for both ADLumin-1 and luciferin (Fig. 4d). The data supported our hypothesis that the larger FWHM of ADLumin-1, whose emission is shorter than that of firefly luciferin, could be beneficial for in vivo imaging.
In vivo imaging with ADLumin-1. To verify the binding of ADLumin-1 to Aβs in a real biologically relevant environment, we explored whether ADLumin-1 can stain Aβ plaques in vivo. In this regard, a 5xFAD mouse brain slice was first incubated with ADLumin-1. As expected, ADLumin-1 provided an excellent contrast for the plaques. The signal to noise ratio (SNR) was 2.93 (Fig. 5a, d). To determine whether ADLumin-1 is capable of labeling Aβ plaques in vivo, we conducted two-photon imaging with a 5xFAD mouse, a widely used AD model.55 We observed that ADLumin-1 could quickly cross the blood–brain barrier (BBB), and provided excellent contrast for cerebral amyloid angiopathy (CAA) on the blood vessels and Aβ plaques (Fig. 5b). The SNR of plaques and CAAs were about 17.0 and 26.0, respectively (Fig. 5 e). The time-course imaging results revealed that the intensity in CAA reached the peak within 1 min, while it was 5 min for the plaques. These results suggested that ADLumin-1 could penetrate BBB and stay in the brain (Supplementary Fig. 5A–C), and it was also an excellent two-photon imaging probe for Aβs in vivo.

To further confirm that ADLumin-1 is indeed able to stain the plaques, we sacrificed the mouse, and sectioned its brain into 20-micron thick slices for histology studies. As expected, the plaques in the brain slice were considerably bright (Fig. 5c, f), confirming that ADLumin-1 could label the plaques in vivo.

To investigate whether ADLumin-1 can be used to detect Aβs in vivo with a noninvasive imaging setup, we used an IVIS imaging system to conduct image acquisition. 4-month old 5xFAD mice (n = 4) and age-matched wild-type (WT) were used, and a solution of ADLumin-1 (4 mg/kg) was injected intravenously. Images were captured at 15-, and 30-min after the injection with open filter setting. Although the emission peak of ADLumin-1 is relatively shorter in comparison of other NIRF dyes for brain imaging, we observed considerable strong signals from the brain area, and the differences between 5xFAD and WT

**Fig. 3 In vitro characterization of fluorescence and chemiluminescence properties of ADLumin-1 in the presence of Aβs.**

**a** Fluorescence spectra of ADLumin-1 alone (red) and with Aβ40 aggregates (black); **b** Chemiluminescence spectra of ADLumin-1 alone (red) and with Aβ40 aggregates (black); **c** Molecule docking of ADLumin-1 (blue) with Aβ fibrils (PDB:5OQV); **d** In vitro chemiluminescence images of ADLumin-1 alone and with Aβ40 aggregates in PBS; **e** Quantification of chemiluminescence intensity in **d**; **f** In vitro chemiluminescence images of ADLumin-1 alone and with Aβ40 aggregates in mouse brain homogenate; **g** Quantification of chemiluminescence intensity in **f**. Data are represented as mean ± s.d. with n = 3 biologically independent samples. P = 0.0005 (**e**), P < 0.0001 (**g**). The P-values were generated by Graphpad Prism 8 with two-tailed unpaired t-test; ***P-value < 0.001, ****P-value < 0.0001. Source data underlying **e** and **g** are provided as Source Data file.
were 1.7-fold and 1.8-fold at 15- and 30-min, respectively (Fig. 6a). To further confirm the signals originated from brain, we also conducted imaging with multiple filters from 500 to 840 nm (Supplementary Fig. 6A). We found that the highest signals were from the 640 nm filter, with which the difference with 640 nm was 1.7-fold. This is similar to the open filter setting. These results suggested that the majority of the signals are from brains (640 nm), but not from shallow locations such as skin.

Interestingly, we also noticed that the chemiluminescence signals from eyes were higher (1.6-fold) in the 5xFAD group than that in WT group (Fig.6c, d). This is consistent with our previous report, in which we showed that NIRF probe CRANAD-X \( (X = -2, -3, -30, -58, \) and \(-102) \) could detect the A\( \beta \) content in eyes\(^{56}\). Even more intriguingly, we found that the signals from noses were also stronger in the 5xFAD group (1.7-fold, Supplementary Fig. 6B). No significant difference was observed from the palms of the WT and 5xFAD groups (Supplementary Fig. 6D).

### Dual-amplification of signal via chemiluminescence resonance energy transfer (DAS-CRET)

Although we demonstrated that ADLumin-1 was a smart chemiluminescence probe for A\( \beta \)s via testing in pure solutions, brain homogenate, and in vivo brain and eye imaging, its emission peak was still relatively short. To overcome this problem, we speculated that CRET could be used to shift the detectable emission into the near infrared (NIR) window. Since CRET does not need external excitation and has no interference from the cross-excitation of the acceptor\(^{57-59}\), data analysis is easier. More importantly, better penetration could be achieved, due to the longer emission of the acceptor. The requirements for CRET are similar to FRET\(^{60}\), which requires that the donor and acceptor are conjugated through a linker or proteins engineered in close proximity (normally <10 nm). The closer proximity of the donor-acceptor and more spectral overlap of donor emission and acceptor excitation, the higher the transfer efficiency.

Interestingly, our previous work demonstrated that non-conjugated FRET was feasible in solutions with two small molecules that both have binding capacity to A\( \beta \) species, because the pair have a high probability of randomly incorporating themselves into the beta-sheets of A\( \beta \)s within 10 nm proximity to generate a viable FRET signal\(^{61}\). However, this technology was not very efficient and nearly impossible to apply in vivo, due to its short excitation and cross-excitation of the acceptor, which makes it complex and hard to tease out the FRET effect. Although CRET has been used for various biological studies and in vivo imaging, most of CRET pairs have no signal amplification (turn-on) for either donor or acceptor upon target binding. Here we hypothesized that dual-amplification of signal-CRET (DAS-CRET) could be feasible if both the donor and acceptor can bind to the target and amplify (turn-on) their luminescence signals (Fig. 7a). In this report, we used the nonconjugated pair of ADLumin-1 and CRANAD-
NIRF probe for Aβ solutions. Previously, we reported that CRANAD-3 was a turn-on prone proteins. This strategy can also be extended to detect other misfolding-homogenates, and in vivo whole brain imaging. We believe βCRET was achievable with Aβs. To the best of our knowledge, the well-overlapped spectra of ADLumin-1 emission and CRANAD-3 excitation also contributed to the highly efficient CRET (Supplementary Fig. 6C).

To further investigate whether this CRET is feasible in a brain-like environment, we conducted similar experiments with mouse brain homogenate. Indeed, we observed an apparent CRET signal like environment, we conducted similar experiments with mouse brain homogenate. Indeed, we observed an apparent CRET signal.

We first tested whether DAS-CRET was possible in PBS solutions. Previously, we reported that CRANAD-3 was a turn-on NIRF probe for Aβs in vitro and in vivo. In this test, we incubated ADLumin-1, CRANAD-3, and Aβ aggregates in PBS buffer, and found that CRET between ADLumin-1 and CRANAD-3 was very obvious in the presence of Aβs, while there is no observable CRET in the absence of aggregates (Fig. 7b). Remarkably, the CRET was not only FRETing into longer emission, but it also significantly amplified the signals. Compared to the CRET pair without Aβs, the signal was about a 133-fold increase with the presence of Aβs at 660 nm (Fig. 7b). This large amplification is due to dual signal amplification that arose from turn-on effects from both ADLumin-1 and CRANAD-3 in the presence of Aβs. To the best of our knowledge, this phenomenon is exceptional for CRET. This highly efficient CRET is also likely due to the very close proximity of the pair when they randomly inserted into beta-sheets of Aβ aggregates, which are consisted of abundant fibrils that contains numerous beta-sheets in parallel or anti-parallel arrangement. In addition, the well-overlapped spectra of ADLumin-1 emission and CRANAD-3 excitation also contributed to the highly efficient CRET (Supplementary Fig. 6C).

To further investigate whether this CRET is feasible in a brain-like environment, we conducted similar experiments with mouse brain homogenate. Indeed, we observed an apparent CRET signal at 640 nm (Fig. 7c), which is corresponding to the emission of CRANAD-3. The CRET signal was increased 11.4-fold if Aβs were added to the homogenate. Remarkably, we found that the signals from DAS-CRET were 2.38-fold higher than that from the non-CRET group (without CRANAD-3) at 640 nm, suggesting that DAS-CRET is achievable in a real biologically relevant environment.

To accurately analyze the signal amplification, FRET is also coupled with spectral unmixing technique to separate the signal contributions from the donor and the acceptor. Although spectral unmixing has been rarely explored for CRET, we speculated that spectral unmixing could be feasible for our DAS-CRET. Indeed, the detection sensitivity could be further increased via spectral unmixing. In Fig. 7d, it is very clear that the unmixed spectrum (red line) is similar to the emission of CRANAD-3 after unmixing. Remarkably, the difference between CRET and non-CRET could reach 31-fold in the brain-like environment.
In vivo DAS-CRET imaging. To explore whether the CRET pair can be used in alive animals, we first mimicked the in vivo environment via subcutaneously injecting the mixture of the CRET pair with Aβs into a nude mouse at the ventral hind limb, and ADLumin-1 + Aβs as the control group (Fig. 8a). At 15 min post injection, the signal from the CRET group (right) was 1.34-fold higher than that from the control site (left) (Fig. 8b), suggesting that the nonconjugated CRET pair can be used in vivo. To investigate whether the CRET pair can be used for deep locations, we flipped the above mouse to acquire images from the dorsal side (the thickness from the injection site to the dorsal surface is about 1.2 cm). As expected, signals could be detected. Remarkably, we found the difference between the CRET group and the control group could be easily observed (1.42-fold), indicating the pair can be used for imaging at deep locations (Fig. 8b). To further achieve more accurate information about the efficiency of CRET in vivo, we conducted spectral unmixing imaging with 18 filters to collect signal from 500 to 840 nm. The unmixed spectra closely resemble the spectra of ADLumin-1 + Aβs (green), and CRET + Aβs (red), respectively (Fig. 8c, d). After spectral unmixing, the difference between the control and the CRET groups reached 2.72-fold (Fig. 8c middle). From the composite image, it is clear that the signal from the CRET site is from long emission, while the signal from the control site is from short emission (Fig. 8c right). Taken together, these results suggested that in vivo DAS-CRET was feasible and spectral unmixing imaging was applicable for in vivo imaging, and larger margin of differences can be achieved via spectral unmixing.

To validate the feasibility of CRET in vivo brain imaging, we injected (iv) a solution containing both ADLumin-1 and CRANAD-3, and images were collected with an open filter and 18 filters from 500 to 840 nm. With the open filter setting, we observed 2.04-fold differences between the 5xFAD group and the WT group at 15 min after the injection (Fig. 9a, c). With the 640 nm filter, the AD group showed 2.25-fold higher signal than the control WT group (Fig. 9d). Moreover, as expected, the CRET pair provided higher luminescence signals at 640 nm than that of ADLumin-1 alone in both AD and WT groups, and the increase was 2.10- and 1.66-fold, respectively (Fig. 9b). To investigate whether spectral unmixing can be applied to this in vivo imaging study, we conducted spectral unmixing with the previously described method. Indeed, the margin between AD and WT was significantly increased after spectral unmixing, and it reached 3.22-fold from the CRET pair (Fig. 9e).

In our previous studies, we reported that NIRF ocular imaging could be used to differentiate AD and WT mice and monitor therapeutic effect on Aβ-lowering with treatment. In this work, we performed ocular CRET imaging as well, and found that it was feasible and provided a considerably large margin of 2.11-fold between 5xFAD and WT mice (Supplementary Fig. 7).
margin indicated that ocular CRET could be a very useful tool for monitoring the changes in Aβ concentrations. Interestingly, we also noticed that the nose signal was higher from the AD group than that from the WT group with ADLumin-1 alone or with DAS-CRET (Supplementary Fig. 7D).

Discussion
In this report, we demonstrated that ADLumin-1 is a smart chemiluminescence probe for Aβs in vitro and in vivo. We also revealed that DAS-CRET was feasible via a nonconjugated dual-turn-on CRET pair with the combination of a smart chemiluminescence probe and a smart NIRF probe. Although we only performed validations with Aβ species, we believe that the strategy for probe designing and CRET method can be extended to other misfolding proteins such as tau, alpha-synucleins, TDP-43, amylin, fibrinogen, prion, fused in sarcoma (FUS) protein, SOD, and transthyretin31,64. These proteins probably also meet the designing requirements, which include hydrophobic beta-sheets for binding of specific small molecule probes to turn-on luminescence, and the close proximity of abundant beta-sheets to randomly positioning the paired nonconjugated probes for CRET occurrence. It is known that not all amyloid proteins exist in brains, some misfolded protein deposits can be found in the skin and other places. Considering that our method has relatively deep penetration as we demonstrated in the mimicked imaging (Fig. 8), our CRET strategy is likely applicable for this purpose.

For most hydrophobic fluorescence probes (for nonactivatable probes), the restricted conformation of a probe and the hydrophobicity of the residing environment of the probe have strong influence on the turn-on effect of fluorescence31,43,65–67. Similarly, this principle can be applied to chemiluminescence probes. ADLumin-1, which is hydrophobic, showed low efficiency of chemiluminescence in the pure solutions (10% DMSO) without Aβ aggregates, likely because of the free rotation of the carbon–carbon bond in ADLumin-1. In contrast, upon binding to Aβ fibrils, the rotation is rigidly restricted to give rigid conformational rigidifying could significantly enhance the chemiluminescence signal. In addition, like smart fluorescence probes, the chemiluminescence efficiency can be significantly enhanced if the probe binds to hydrophobic micro-environment. This is exactly the case for the binding of ADLumin-1 and Aβ fibrils. The observed substantial blue-shift of emission of the probe with Aβs in the fluorescence studies (Supplementary Fig. 2A), and 2) supported that ADLumin-1 was binding to a hydrophobic environment, which was further agreed by molecular docking results, which revealed that ADLumin-1 preferred to bind to the hydrophobic groove formed by Phe19, Ala21, Val24, Asn27, and Ile31 (Fig. 3c).
responses to O₂, the enhancement of ADLumin-1 signal to ROS is relatively small. Our studies suggested that the auto-oxidation of ADLumin-1 was related to O₂ levels, and this oxidation could be utilized for in vivo imaging. The mechanism of auto-oxidation has not been well studied. Although full elucidation of the mechanism needs more intensive investigation, we believe that the larger FWHM could also provide larger spectral overlap (>2000) (Supplementary Fig. 8) and its large FWHM. In addition, we demonstrated that spectral unmixing can significantly improve the detection sensitivity both in vitro and in vivo for CRET imaging.

Previously, we demonstrated that NIRF probes CRANAD-X could be used to image Aβ contents in eyes of AD mice. Consistent with this report, here we showed that higher luminescence signal from AD noses is also quite intriguing. A few contributors, ADLumin-1 and its analogues could be used as O₂ sensors in future studies.

Chemiluminescence has been used in many other fields such as cancers, diabetes, and infectious diseases. However, to the best of our knowledge, none has been reported for brain disorders including AD. It is also quite challenging to apply CRET for brain imaging. Fortunately, we successfully demonstrated that it was feasible in vivo, as the nonconjugation of the pair could be an advantage to avoid high molecular weight for probe designing. We believe that the nonconjugation strategy can be easily adapted by other groups for other misfolding proteins.

Signal amplification is always beneficial for imaging. In this report, we showed that the chemiluminescence of ADLumin-1 could be amplified (turned-on) by Aβ species. We further validated that the emission of ADLumin-1 could be pushed into the NIR window via CRET. Our images showed impressive signal to noise ratio (SNR). This is likely due to no excitation leakage and autofluorescence. Since it is difficult to have deep penetration from short chemiluminescence, the signal detected at 640 nm is primarily from CRET. In addition, we demonstrated that spectral unmixing can significantly improve the detection sensitivity both in vitro and in vivo for CRET imaging.

Several surprising results were discovered from our studies. Although ADLumin-1 has a moderately short chemiluminescence emission peak, it was an astonishment that ADLumin-1 provided acceptable tissue penetration (5–7% light penetration for the whole body of a mouse (Figs. 4c, d, and 8)) and could be used for in vivo mouse brain imaging. This is probably due to its high SNR (>2000) (Supplementary Fig. 8) and its large FWHM. In addition, the larger FWHM could also provide larger spectral overlap between the donor and the acceptor for CRET. We believe that broadening the FWHM could be utilized for designing chemiluminescence probes in the future. Our results also suggested that, at the same emission wavelength, chemiluminescence imaging could have much better tissue penetration, which is consistent with a previous report that claimed 4-cm tissue penetration could be achieved with chemiluminescence imaging at 800 nm emission.

Recently, great progression has been achieved for developing new chemiluminescence probes and their application. Most of chemiluminescence probes are dependent on ROS reactions and most of the probes have been used to detect ROS in solutions, cells, and in vivo. Surprisingly, we found that ADLumin-1 was much more sensitive to O₂ (27-fold-change), and the responses were very quick (within seconds). Compared to the responses to O₂, the enhancement of ADLumin-1 signal to ROS is relatively small. Our studies suggested that the auto-oxidation of ADLumin-1 was related to O₂ levels, and this oxidation could be utilized for in vivo imaging. The mechanism of auto-oxidation has not been well studied. Although full elucidation of the mechanism needs more intensive investigation, we believe that ADLumin-1 and its analogues could be used as O₂ sensors in future studies.
reports have claimed that noses in AD patients have higher Aβ contents. Further validation in patients and AD mice is still needed.

Normally, to analyze the Aβ contents from brain tissue homogenate or CSF, certain processes are needed after homogenization. The post-homogenization processes include extraction with SDS, TBS and/or formic acid, and centrifugation to separate supernatants and pellets, which are necessary for ELISA analysis, the most used method for reporting Aβ concentrations. It is well-known that these steps strongly contribute to the poor reproducibility of ELISA. In this report, our in vitro experimental results showed that ADLumin-1 could detect the presence of Aβ species in brain homogenate, indicating that ADLumin-1 could be used for reporting Aβ concentrations without any processing. The optimization is still ongoing, and we will report the results in due course.

In summary, we reported that ADLumin-1 was a smart chemiluminescence probe for Aβs in vitro and in vivo, and DAS-CRET was feasible for detecting Aβ contents in the NIR window. Considering the tissue penetration of DAS-CRET, it is possible to use our method for brain studies on large animals such as mammals. In addition, our results also showed that the Aβ contents in eyes could be detected. We believe that our methods have strong potential for preclinical animal studies and could be possibly applied for translational studies in the future.

Methods

Oxygen and ROS sensitivity of ADLumin-1. A 100.0 μl DMSO solution of ADLumin-1 (200.0 μM) was added to a well in a 96-well plate. One group was bubbled with oxygen for 5 s at different time points, and the control group was sealed without bubbling. Once the bubbling was over, the plate was subjected to chemiluminescence intensity recording with the IVIS system with the open filter setting (500–840 nm). For ROS tests, a PBS solution (240 μl) was incubated in an eppendorf tube. To each of above tubes, different ROS (250.0 μM, H2O2 30 μM, ClO− 30 μM, TBHP 30 μM, and KO2 30 μM) was added, respectively. Then, a solution of ADLumin-1 in DMSO (30 μM, 250.0 μM) was added. Finally, 100.0 μl of the resulting solution was transferred into a well of 96-well plate, and triplicated samples were prepared. Chemiluminescence images were obtained with an IVIS system under the open filter (500–840 nm).

Preparation of Aβ40 aggregates. 1.0 mg of Aβ40 peptide (TFA) was suspended in 1% ammonia hydroxyl solution (1.0 ml). Then 100 μl of the resulting solution was diluted 10-fold with PBS buffer (pH 7.4) and stirred at room temperature for 3 days. Transmission electron microscopy and Thioflavin T solution test were used to confirm the formation of aggregates.

In vitro fluorescence spectra of ADLumin-1 with Aβ40 aggregates. To test the interactions of ADLumin-1 with Aβs, we used the following three-step procedure. In step 1, 1.0 ml of double-distilled water was added to a quartz cuvette as a blank control, and its fluorescence was recorded with the same parameters used for ADLumin-1. In step 2, the fluorescence of an ADLumin-1 solution (1.0 mL, 250.0 nM) was recorded with excitation at 410 nm and emission from 450–700 nm. In step 3, to the above ADLumin-1 solution, 10.0 μl of Aβs (250.0 μM stock solution in PBS buffer for Aβ40 aggregates) were added to make the final Aβ concentration of 250.0 nM. Fluorescence readings from this solution were recorded as described in...
step 2. A blank control from step 1 was used to correct the final spectra from steps 2 and 3.

In vitro chemiluminescence study. A PBS solution (95 μL) or brain homogenate (95 μL) was incubated in an eppendorf tube in the presence or absence of Aβ40 aggregates (final concentration 12.5 μM). To each of the above tubes, a solution of ADLumin-1 in DMSO (50 μL, 250 μM) was added. For the CRET test, 5.0 μL DMSO solution of CRANAD-3 (250.0 μM) and 5.0 μL DMSO solution of ADLumin-1 (250.0 μM) were added (Aβ40 aggregates final concentration 12.5 μM). Finally, 100 μL of the resulting solution was transferred into a well of 96-well plate, and triplicated samples were prepared. Chemiluminescence images were obtained with an IVIS system under the open filter (500–840 nm) or specific filters.

Binding affinity of ADLumin-1 with Aβs. A series of solutions containing 250.0 nM of ADLumin-1 and various concentrations of Aβ40 aggregates (0.0, 25.0, 100.0, 250.0, 500.0, 1000.0, 2000.0, 4000.0, and 8000.0 nM) were subjected to fluorescence spectral recording (Ex = 420 nm, Em = 450–700 nm). The emission readings at 515 nm were used for a nonlinear specific binding fitting.

In vitro histochemical study. A fresh brain tissue from a 24-month-old APP/PS1 mouse was fixed in 4% formaldehyde for 24 h and transferred into 30% sucrose at 4 °C until the tissue sank. Then the tissue was embedded in OCT with gradual cooling over dry ice. The OCT embedded tissue block was sectioned into 25-μm slice with a cryostat. 25 μL of DMSO solution of CRANAD-3 (250.0 μM) was prepared and cooled over dry ice. The OCT embedded tissue block was sectioned into 25-μm slice with a cryostat, then the slice was covered with FluoroShield mounting medium (Abcam) and sealed with nail polish. Florescence images were obtained using the Nikon Eclipse 50i microscope with a blue light excitation channel.

In vivo two-photon imaging. A 15-month-old 5xFAD female mouse was anesthetized with 2% iso-flurane, and a cranial imaging window was surgically prepared in the ventral side with the open filter (500–840 nm) and specific filters. Living Image 4.2.1 software (PerkinElmer) was used for data analysis. Chemiluminescent signals from the eyes were recorded before and after i.v. injection of the probe. Chemiluminescent signals from the eyes were captured at 0 and 45 min after i.v. injection of the probe. Sequence images were captured at 15 min after probe injection with the following parameters: sequence filter from 500 to 840 nm with an interval of 20 nm; Exposure time is 30 s, FOV = D. Spectral unmixing was performed with Living Image 4.2.1 software, and guided unmixing method was selected. To evaluate our imaging results, an ROI was drawn around the brain or the eye region. Student t-test was used to calculate P-values.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability. All data supporting the findings of this study are included in the Article and its Supplementary Information. Source data are provided with this paper.

Received: 19 January 2020; Accepted: 13 July 2020; Published online: 13 August 2020

References
1. Massoud, T. F. & Gambhir, S. S. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 17, 545–580 (2003).
2. Rao, J., Dragulescu-Andrasi, A. & Yao, H. Fluorescence imaging in vivo: recent advances. Curr. Opin. Biotechnol. 18, 17–25 (2007).
3. Lakowicz, J. Principles of Fluorescence Spectroscopy (Plenum Publishing Corporation, 1999).
4. Rice, B. W. & Contag, C. H. The importance of being red. Nat. Biotechnol. 27, 624–625 (2009).
5. Kobayashi, H., Ogawa, M., Alford, R., Choyke, P. L. & Uran, Y. New strategies for fluorescent probe design in medical diagnostic imaging. Chem. Rev. 110, 2620–2640 (2010).
6. Ueno, T. & Nagano, T. Fluorescent probes for sensing and imaging. Nat. Methods 8, 642–645 (2011).
7. Miao, Q. et al. Molecular afterglow imaging with bright, biodegradable polymer nanoparticles. Nat. Biotechnol. 35, 1102–1110 (2017).
8. Hananya, N. & Shabat, D. A glowing trajectory between bio- and chemiluminescence: from luciferin-based probes to triggerable dioxetanes. Angew. Chem. Int. Ed. Engl. 56, 16454–16463 (2017).
9. Hananya, N. & Shabat, D. Recent advances and challenges in luminescent imaging: bright outlook for chemiluminescence of dioxetanes in water. ACS Cent. Sci. 5, 949–959 (2019).
10. Suzuki, K. & Nagai, T. Recent progress in expanding the chemiluminescent toolbox for bioimaging. Curr. Opin. Biotechnol. 48, 135–141 (2017).
11. Lee, D. et al. In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat. Mater. 6, 765–769 (2007).
12. Roda, A., Pasini, P., Mirasoli, M., Micheli, E. & Guardigli, M. Biotechnological applications of bioluminescence and chemiluminescence. Trends Biotechnol. 22, 295–303 (2004).
13. Shuhendler, A. J., Pu, K., Cui, L., Uetrecht, J. P. & Rao, J. Real-time imaging of oxidative and nitrosative stress in the liver of live animals for drug-toxicity testing. Nat. Biotechnol. 32, 373–380 (2014).
14. Baumes, J. M. et al. Storable, thermally activated, near-infrared chemiluminescent dyes and dye-stained microparticles for optical imaging. Nat. Chem. 2, 1025–1030 (2010).
15. Lee, I.-J. H. O., Yoo, D.-H., Khang, G.-S. & Lee, D.-W. Detection of hydrogen peroxide in vitro and in vivo using peroxalate chemiluminescent micelles. Bull. Korean Chem. Soc. 21, 2187–2192 (2011).
16. Zhao, H. et al. Characterization of coelenterazine analogs for measurements of Renilla luciferase activity in live cells and living animals. Mol. Imaging 3, 43–54 (2004).
17. Broussard, L. L., Stokes, C. & Contag, C. H. Chemiluminescence imaging of superoxide anion detects beta-cell function and mass. PLoS ONE 11, e0146601 (2016).
18. Selkoe, D. J. Resolving controversies on the path to Alzheimer’s therapeutics. Nat. Med. 17, 1060–1065 (2011).
19. Nordberg, A. Molecular imaging in Alzheimer’s disease: new perspectives on biomarkers for early diagnosis and drug development. Alzheimers Res Ther. 3, 34 (2011).
20. Hintersteiner, M. et al. In vivo detection of amyloid-beta deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23, 577–583 (2005).
21. Skovronsky, D. M. et al. In vivo detection of amyloid plaques in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 97, 7509–7614 (2000).
22. Nesterov, E. E. et al. In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew. Chem. Int. Ed. 44, 5452–5456 (2005).
23. Higuchi, M. et al. 19F and 1H MRI detection of amyloid beta plaques in vivo. *J. Am. Chem. Soc.* 139, 12550–12558 (2017).

24. Wadghiri, Y. Z. et al. Detection of Alzheimer’s amyloid in transgenic mice using magnetic resonance microimaging. *Magn. Reson. Med.* 50, 293–302 (2003).

25. Bolognesi, M. L., Gandini, A., Prati, F. & Ussiassi, E. From companion diagnostics to theranostics: a new avenue for Alzheimer’s disease? *J. Med. Chem.* 59, 7759–7770 (2016).

26. Run, C. et al. Design, synthesis, and testing of difluoroboron-derivatized curcumin as near-infrared probes for in vivo detection of amyloid-beta deposits. *J. Am. Chem. Soc.* 131, 15257–15262 (2009).

27. Ran, C. & Moore, A. Spectral unmixing imaging of wavelength-responsive fluorescent probes: an application for the real-time report of amyloid Beta species in Alzheimer’s disease. *Mol. Imaging Biol.* 14, 293–300 (2012).

28. Zhang, X. et al. Design and synthesis of curcumin analogs for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid Beta species in Alzheimer’s disease. *J. Am. Chem. Soc.* 135, 16397–16409 (2013).

29. Zhang, X. et al. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. *Proc. Natl Acad. Sci. USA* 112, 9734–9739 (2015).

30. Zhang, X. & Ran, C. Dual functional small molecule probes as fluorophore and linker for misfolding proteins. *Curr. Org. Chem.* 17, 580–593 (2013).

31. Jakob-Roetnete, R. & Jacobsen, H. Alzheimer’s disease: from pathology to therapeutic approaches. *Angew. Chem. Int. Ed. Engl.* 48, 3030–3059 (2009).

32. Chang, W. M. et al. ANCA: a family of fluorescent probes that bind and stain amyloid plaques in human tissue. *ACS Chem. Neurosci.* 2, 249–255 (2011).

33. Choi, S. R. et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in Alzheimer’s disease. *J. Am. Chem. Soc.* 139, 17338–17341 (2012).

34. Cui, M. et al. Smart near-infrared fluorescence probes with donor-acceptor structure for in vivo detection of beta-amyloid deposits. *J. Am. Chem. Soc.* 136, 3358–3364 (2014).

35. Lv, G., Sun, A., Wei, P., Zhang, N., Lan, H. & Yi, T. A spiropyran-based fluorescent probe for the specific detection of β-amyloid peptide oligomers in Alzheimer’s disease. *Chem. Commun. (Camb.)* 52, 8865–8868 (2016).

36. Fu, W. et al. Rational design of near-infrared aggregation-induced-emission-active probes: in situ mapping of amyloid-beta plaques with ultra-sensitivity and high-fidelity. *Angew. Chem. Int. Ed. Engl.* 131, 3171–3177 (2019).

37. Teoh, C. L. et al. Chemical fluorescent probe for detection of abeta oligomers. *J. Am. Chem. Soc.* 137, 13503–13509 (2015).

38. Shin, J. et al. Harnessing intramolecular rotation to enhance two-photon imaging of abeta plaques through minimizing background fluorescence. *Angew. Chem. Int. Ed. Engl.* 58, 5648–5652 (2019).

39. Sedgwick, A. C. et al. An ESPIT probe for the ratiometric imaging of peroxyxinitrite facilitated by binding to abeta-aggregates. *J. Am. Chem. Soc.* 140, 14267–14271 (2018).

40. Cao, K. J. & Yang, J. Translational opportunities for amyloid-targeting fluorophores. *Chem. Commun. (Camb.)* 54, 9107–9118 (2018).

41. Maeneta, R., Tordesillas, M. & Gonzalez-Gaitano, G. Natural cyclodextrins as efficient boosters of the chemiluminescence of lumines and isoluminol: exploration of potential applications. *J. Phys. Chem. B* 114, 2798–2806 (2010).

42. Green, O. et al. Near-infrared dioxetane luminophores with direct chemiluminescence emission mode. *J. Am. Chem. Soc.* 139, 12343–12348 (2017).

43. Son, S. et al. Chemiluminescent probe for the in vitro and in vivo imaging of cancers over-expressing NQO1. *Angew. Chem. Int. Ed. Engl.* 58, 1739–1743 (2019).

44. Roth-Konforti, M. et al. Ultrasensitive detection of Salmonella and Listeria monocytogenes by small-molecule chemiluminescence probes. *Angew. Chem. Int. Ed. Engl.* 131, 3171–3177 (2019).

45. Faulkner, K. & Fridovich, I. Lumilin and lucigenin as detectors for O2. *Free Radic. Biol. Med.* 15, 447–451 (1993).

46. Teranishi, K. Luminescence of imidazo[1,2-a]pyrazin-3(7H)-one compounds. *Bioorg. Chem.* 35, 82–121 (2007).

47. Krzyminski, K. et al. Chemiluminescent features of 10-methyl-9-(phenoxycarbonyl)acridinum trifluoromethanesulfonates alkyl substituted at the benzene ring in aqueous media. *J. Org. Chem.* 76, 1072–1081 (2011).

48. Barondeau, D. P., Putnam, C. D., Kassmann, C. J., Tainer, J. A. & Getzoff, E. D. Mechanism and energetics of green fluorescent protein chromophore synthesis revealed by trapped intermediate structures. *Proc. Natl Acad. Sci. USA* 100, 12111–12116 (2003).

49. Lamprecht, D. et al. A causal relation between bilirubinemia and oxygen to quantify the cell niche. *PLoS ONE* 9, e97572 (2014).

50. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. *J. Neurosci.* 26, 10129–10140 (2006).

51. Huang, X., Li, L., Qian, H., Dong, C. & Ren, J. A resonance energy transfer between chemiluminescent donors and luminescent quantum-dots as acceptors (CRET). *Angew. Chem. Int. Ed. Engl.* 45, 5140–5143 (2006).

52. Li, P. et al. A new polymer nanoprobe based on chemiluminescence resonance energy transfer for ultrasensitive imaging of intrinsic superoxide anion in mice. *J. Am. Chem. Soc.* 138, 2893–2898 (2016).

53. Zhang, Z., Francis, K. P. & Ansaldi, D. Enhanced detection of myeloperoxidase activity in deep tissues through luminescent excitation of near-infrared nanoparticles. *Nat. Med.* 19, 500–505 (2013).

54. Sapsford, K. E., Berti, L. & Medintz, I. L. Materials for fluorescence resonance energy transfer analysis: beyond traditional donor-acceptor combinations. *Angew. Chem. Int. Ed. Engl.* 45, 4586–4589 (2006).

55. Ran, C., Zhao, W., Moir, R. D. & Ansaldi, D. Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. *PLoS ONE* 6, e19362 (2011).

56. Su, W., Du, M., Lin, F., Zhang, C. & Chen, T. Quantitative FRET measurement based on spectral unmixing of donor, acceptor and spontaneous- excitation emission spectra. *J. Biophotonics* 12, e201800314 (2019).

57. Dueiros, M. et al. Spectral unmixing: analysis of performance in the olfactory bulb in vivo. *PLoS ONE* 4, e44189 (2009).

58. Gandhi, J. et al. Protein misfolding and aggregation in neurodegenerative diseases: a view of pathogeneses, novel detection strategies, and potential therapeutics. *Rev. Neurosci.* 30, 339–358 (2019).

59. Zhou, K. et al. Environment-sensitive near-infrared probe for fluorescent discrimination of abeta and tau fibrils in AD brain. *J. Med. Chem.* 62, 6694–6704 (2019).

60. Walker, A. S., Rahlen, P. R. & Schepartz, A. Rotamer-restricted fluorogenicity of the bis-arsenical ReASH. *J. Am. Chem. Soc.* 138, 7143–7150 (2016).

61. Grabowski, Z. R., Rotkiewicz, K. & Retig, W. Structural changes accompanying intramolecular electron transfer: focus on twisted intramolecular charge-transfer states and structures. *Chem. Rev.* 103, 3899–4032 (2003).

62. Arnold, S. E. et al. Offactory epithilum amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. *Ann. Neural.* 67, 462–469 (2010).

63. Kim, Y. H. et al. Amyloid beta in nasal secretions may be a potential biomarker of Alzheimer’s disease. *Sci. Rep.* 9, 4966 (2019).

64. Mostany, R. & Portera-Cailliau, C. A craniotomy surgery procedure for chronic brain imaging. *J. Vis. Exp.* 12, e8680 (2008).
